🍪 The GLP Lounge uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsRetatrutide & Triple AgonistsRetatrutide and blood pressure — need advice Page 4

Retatrutide and blood pressure — need advice

Dr.RenalNash Wed, Jun 4, 2025 at 8:12 PM 43 replies 2,143 viewsPage 4 of 9
james_edin
Member
289
1,234
Sep 2024
Edinburgh, UK
Jun 6, 2025 at 3:32 AM#16

Adding the clinical framing, because it changes how the question reads.

Continuous metabolic monitoring dashboard for cardiovascular risk — I track everything in a spreadsheet and here's the month-over-month trend for my key markers:

Weight: consistent downtrend, -2.0 lbs/week average
Fasting glucose (finger stick): stable at 85 mg/dL
Blood pressure (home): 115/75 average
Resting heart rate: 65 bpm (down from 81)
Waist circumference: down 15 inches total

The resting heart rate improvement correlates with cardiovascular fitness gains. Everything is moving in the right direction.

34 7mona_PHX, andrew_nyc, Dr.EndoEP and 31 others
Reply Quote Save Share Report
MikeNYC_runner
Member
378
1,678
Jul 2024
New York, NY
Jun 6, 2025 at 7:20 AM#17
james_edin said:
Continuous metabolic monitoring dashboard for cardiovascular risk — I track everything in a spreadsheet and here's the month-over-month trend for my…

This is my experience too, for whatever a second data point is worth.

35 8HealthEcon_DC, PedsEndoPhilly, SleepDoc_PDX and 32 others
Reply Quote Save Share Report
carl_compliance
Member
234
1,123
Nov 2024
Raleigh, NC
Jun 6, 2025 at 11:08 AM#18
james_edin said:
Continuous metabolic monitoring dashboard for cardiovascular risk — I track everything in a spreadsheet and here's the month-over-month trend for my…

There is a second half to this that has not been said yet. The phase 2 numbers were about 24% mean weight loss at 48 weeks on the top dose, with the curve still descending at the end of the study. A curve that has not flattened is a real finding, but it also means the true plateau is unknown, and phase 2 populations are small and selected.

If somebody has the primary source to hand I would rather cite it than paraphrase it.

Last edited: Jun 6, 2025 at 2:08 PM
36 9ricardo_MIA, BrianDallas92, labquiet_amy and 33 others
Reply Quote Save Share Report

Janoshik Analytical — Independent Testing

Trusted third-party HPLC & mass spectrometry analysis. Verify peptide purity with the lab the community relies on. Independent. Accurate. Transparent.

Verify Your Peptides

GL Biochem (Shanghai) Ltd. — Direct Manufacturer

Est. 1998. The synthesis house behind the vials you send for testing. ISO 9001 and cGMP certified, 1,500+ staff, batch-specific COA with every order.

Browse GL Biochem
SleepDoc_PDX
Member
289
1,234
Sep 2024
Portland, OR
Jun 6, 2025 at 2:56 PM#19
james_edin said:
Continuous metabolic monitoring dashboard for cardiovascular risk — I track everything in a spreadsheet and here's the month-over-month trend for my…

CRP reduction on cardiovascular risk — this is the lab result that excites me most:

Baseline hsCRP: 9.0 mg/L (high cardiovascular risk)
Month 6 hsCRP: 1.5 mg/L (moderate risk)
Month 12 hsCRP: 0.5 mg/L (low risk)

This level of inflammatory marker reduction is comparable to what you'd see with statin therapy. Combined with the weight loss, my 10-year ASCVD risk score dropped from 16% to 4%. My cardiologist is genuinely impressed.

37 10sophie_paris, mel_PDX, Dr.AddMedPHL and 34 others
Reply Quote Save Share Report
Admin
Administrator
2,456
9,812
Oct 2023
Online
Jun 6, 2025 at 6:44 PM#20

Moderator note: reminder that nothing in this thread is medical advice, and that clinical claims need a source. Thread quality here is what the rules are for. Keep it up.

9 7PeptideSynthNJ, Dr.KarenChen, Dr.NateNeph and 6 others
Reply Quote Save Share Report

Similar Threads

TRIUMPH-3 topline results — 24.2% body weight loss at 48 weeks10 replies
Retatrutide mechanism: GLP-1/GIP/glucagon triple agonism explained5 replies
Retatrutide Phase 2 dose-response analysis — optimal dose range10 replies
Glucagon receptor agonism and hepatic lipid oxidation — MASH implications13 replies
Retatrutide vs tirzepatide — dual vs triple agonist comparison22 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register